Novartis says biosimilar rituximab accepted for review by FDA
ZURICH (Reuters) - Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Allergy & Immunology | Arthritis | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology | Rituxan